Infection and Vaccines金沙平台注册

金沙手机app平台

金沙手机app平台

We work to protect patients against the burden of influenza, respiratory syncytial virus (RSV) and bacterial infections, particularly those resistant to current antibiotics.

In Europe, antimicrobial resistance results in 25,000 deaths from hospital-acquired infections, while there are 3-5 million severe cases of influenza each year worldwide. RSV disease is the leading cause of hospitalisation in children under one year of age in the United States

Demand for health interventions to address these burdens of disease remains high and, through working with the wider infection community, AstraZeneca aims to translate science into solutions to address global challenges faced in these disease areas.

金沙手机app平台

Infectious diseases are the second-leading cause of death worldwide, after heart disease, and are responsible for 更多 deaths annually than cancer.

  • 金沙平台注册

    AMR is a major public health threat. As bacteria develop resistance to current antibiotics, deadly infections could, again, become uncontrollable.


    金沙官网登录注册
  • 金沙平台注册

    Seasonal influenza is a serious public health problem that causes severe illness and death in high-risk populations.


    金沙官网注册开户

金沙平台注册

金沙平台注册

金沙平台注册

金沙平台注册

金沙平台注册

金沙平台注册

金沙平台注册

金沙平台注册


Our pipeline金沙平台注册

金沙手机app平台

金沙手机app平台

We cannot provide 详细ed 资讯rmation 关于 our prescription medicines on this website, in compliance with regulations. Our medicines are approved in individual countries for specific uses and the 资讯rmation we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out 更多 关于 our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, 资讯rmation on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice 关于 medicines.


Synagis 金沙平台注册

palivizumab

Fluenz Tetra/FluMist Quadrivalent金沙平台注册

influenza vaccine live, intra-nasal

金沙手机app平台


金沙手机app平台

and help us deliver life-changing medicines

Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.


Veeva ID: Z4-17493    

Date of next review: 07/06/2021